Treatment of Relapsing Polychondritis With Dapsone

Barranco, Vincent P.; Minor, Dwane B.; Solomon, Herman

doi:10.1001/archderm.1976.01630330048013

Cited by 79 publications

(9 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the relapsing and chronic nature of this disorder, attempts have been made to utilize steroid‐sparing agents. Previous studies have pointed to the efficacy of dapsone as a single agent 10,11 . Other reportedly successful agents include azathioprine, methotrexate, cyclophosphamide, and cyclosporine 12–14 .…”

Section: Discussionmentioning

confidence: 99%

Relapsing polychondritis

et al. 2003

View full text Add to dashboard Cite

A 43-year-old Chilean man presented with a 5-month history of progressive hypertrophy of the ears bilaterally. He was seen initially by a dermatologist in Chile for complaints of erythema and swelling of the ears, and had been treated unsuccessfully with topical steroids and antimicrobial ointments. On presentation to our clinic, the hypertrophy had stabilized and the erythema had resolved, but he complained of decreased hearing due to narrowing of the external auditory canal. Associated symptoms included occasional pruritus, but he denied any pain. He also denied a history of sinus problems, respiratory symptoms, ocular pain, chest pain, and arthralgias. Physical examination revealed firm hypertrophy of the collagenous areas of both ears, sparing the ear lobes (Fig. 1). No pain was elicited on palpation. No conjunctivitis was noted and the nasal passages were clear. His chest was clear to auscultation. Histologic examination revealed a minimal perivascular infiltrate of lymphocytes and plasma cells in the dermis with fibrosis of the subcutis (Fig. 2). Blood tests showed a normal complete blood count, antinuclear antibody, and rheumatoid factor. Anti-collagen II antibodies were elevated at 29.2 Eu/ml (normal, 0-20 Eu/ml; borderline, 20-25 Eu/ml; elevated, > 25 Eu/ml).

show abstract

Section: Discussionmentioning

confidence: 99%

Relapsing polychondritis

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Many cases do well on steroid therapy as did our case. Good results have also been reported with dapsone (Barranco et al, 1976;Martin et al, 1976) but occasionally more potent and potentially more toxic immunosuppressant therapy is required (Herman, 1981).…”

Section: Discussionmentioning

confidence: 99%

Relapsing Polychondritis with Multifocal Neurological Abnormalities

Willis

Atack

Kraag

1984

Can. j. neurol. sci.

View full text Add to dashboard Cite

ABSTRACT:A sixty-five year old woman developed relapsing polychondritis with three of the diagnostic criteria established by McAdam et al. (1976), namely bilateral auricular chondritis, ocular inflammation and both cochlear and vestibular dysfunction. Many authors have mentioned other neurological symptoms including unilateral facial weakness. This patient is the first case described with bilateral facial weakness and cerebral manifestations.Relapsing polychondritis, an uncommon, recurrent, inflammatory disorder affecting the cartilaginous tissues of the body (Jaksch-Wartenhorst, 1923; Herman, 1981), is regularly associated with audiovestibular dysfunction (Bollet et al., 1969; Cody et al., 1971; McAdam et al., 1976; Ridgway et al., 1979). McAdam et al. (1976) and Ridgway et al. (1979) have mentioned other neurological symptoms including unilateral facial weakness. We recently observed a patient with polychondritis and multifocal neurological abnormalities. We believe this is the first case described with bilateral facial nerve palsy and with cerebral manifestations.

show abstract

“…8 It is a parent compound of the sulfone drugs and interferes with folate metabolism by competitive inhibition of para-amino benzoic acid. It was first reported by Barranco in 1976 as an effective treatment in RP and has been used as a single agent. 43 However, side-effects are common (e.g.…”

Section: Mild Diseasementioning

confidence: 99%

“…It was first reported by Barranco in 1976 as an effective treatment in RP and has been used as a single agent. 43 However, side-effects are common (e.g. nausea, headache, lethargy, nausea, rashes, fevers, and anemia).…”

Section: Mild Diseasementioning

confidence: 99%

Relapsing Polychondritis: Systemic and Ocular Manifestations, Differential Diagnosis, Management, and Prognosis

Yoo¹,

Chodosh²,

Dana³

2011

Seminars in Ophthalmology

View full text Add to dashboard Cite

Relapsing polychondritis (RP) is a rare systemic autoimmune disease characterized by episodic inflammation of cartilaginous tissues throughout the body. It is distinguished by recurrent bouts of inflammation, which lead to the permanent destruction of the involved structures. It can be a life-threatening, debilitating, and frightening disease and is often difficult to diagnose in its early stages. Ocular manifestations have been reported to occur in up to 65% of cases and include proptosis, eyelid edema, extraocular muscles palsy, episcleritis, scleritis, conjunctivitis, corneal infiltrate, peripheral ulcerative keratitis, corneal thinning or perforation, iridocyclitis, cataract, retinopathy, exudative retinal detachment, and optic neuritis. Corticosteroids remain the mainstay of treatment for RP; however, other treatment modalities include nonsteroidal anti-inflammatory drugs, colchicine, dapsone, and immunomodulatory drugs. This article reviews the literature and summarizes the epidemiology, pathogenesis, clinical features, treatment, and prognosis of the systemic and ocular manifestations of RP.

show abstract

Treatment of Relapsing Polychondritis With Dapsone

Cited by 79 publications

References 7 publications

Relapsing polychondritis

Relapsing polychondritis

Relapsing Polychondritis with Multifocal Neurological Abnormalities

Relapsing Polychondritis: Systemic and Ocular Manifestations, Differential Diagnosis, Management, and Prognosis

Contact Info

Product

Resources

About